IL6R and breast cancer: This indicates that IL-6 trans-signaling is predominately mediated by soluble CD126 to regulate IL-6-dependent SOCS3 suppression and sustained activation of the JAK/STAT pathway in MDSCs, as well as coordinates the differentiation and immunosuppressive activity of MDSCs in breast cancer.